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Abstract
Introduction: Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving
vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine.
Balancing this concern is the known higher risk of cholera and of complications of pregnancy should cholera occur in these
women, as well as the lack of expected adverse events from a killed oral bacterial vaccine.
Methodology/Principal Findings: From January to February 2009, a mass rBS-WC vaccination campaign of persons over
two years of age was conducted in an urban and a rural area (population 51,151) in Zanzibar. Pregnant women were
advised not to participate in the campaign. More than nine months after the last dose of the vaccine was administered, we
visited all women between 15 and 50 years of age living in the study area. The outcome of pregnancies that were
inadvertently exposed to at least one oral cholera vaccine dose and those that were not exposed was evaluated. 13,736
(94%) of the target women in the study site were interviewed. 1,151 (79%) of the 1,453 deliveries in 2009 occurred during
the period when foetal exposure to the vaccine could have occurred. 955 (83%) out of these 1,151 mothers had not been
vaccinated; the remaining 196 (17%) mothers had received at least one dose of the oral cholera vaccine. There were no
statistically significant differences in the odds ratios for birth outcomes among the exposed and unexposed pregnancies.
Conclusions/Significance: We found no statistically significant evidence of a harmful effect of gestational exposure to the
rBS-WC vaccine. These findings, along with the absence of a rational basis for expecting a risk from this killed oral bacterial
vaccine, are reassuring but the study had insufficient power to detect infrequent events.
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Introduction
The recombinant cholera toxin B subunit, killed whole-cell oral
cholera (rBS-WC, Dukoral) vaccine, has been found to be safe and
protective in a range of settings over the last 30 years [1,2,3]. This
vaccine is mainly used by tourists visiting endemic areas [4] where
the control of cholera has traditionally been based on safe water
supply, sanitation and health education [5]. A more affordable
oral cholera vaccine which could be used more widely in endemic
settings has recently been developed, licensed, and prequalified for
purchase by UN agencies [6]. This second generation killed oral
cholera vaccine (Shanchol) is composed of a different set of
V.cholerae strains than the rBS-WC vaccine, includes not only O1
but also an O139 strain, does not include the recombinant B
subunit (rBS), therefore does not require buffer for administration,
and has afforded 66% protection during a 3 year trial in Kolkata,
India [7]. In early 2010, the Strategic Advisory group of the World
Health Organization (WHO) recommended that oral cholera
vaccines be used preventively as well as reactively in the
management of cholera outbreaks [8].
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Since cholera tends to affect all age groups in endemic settings
and during outbreaks, mass vaccination is considered an important
vaccine deployment strategy. To achieve maximum impact of
mass cholera vaccination, it is crucial to immunize the highest
possible percentage of the population at risk. This includes women
in the reproductive age group, defined here as being between 15
and 50 years old. In endemic and epidemic settings, women are at
high risk for cholera and other diarrhoeal diseases, not least
because mothers tend to be exposed to infectious children [9].
Without prompt rehydration, cholera during pregnancy can result
in abortions, premature childbirth and maternal death [10,11].
There are good reasons for women in the reproductive age group
in endemic areas to participate in interventions that prevent
cholera. Excluding potentially pregnant women from mass
vaccination campaigns is logistically and ethically challenging.
But administering oral cholera vaccines to this highly vulnerable
population causes a dilemma since the safety of the vaccine during
pregnancy has not been documented. There are several reasons
why it is thought that oral cholera vaccines are unlikely to have a
harmful effect on foetal development. First, the bacteria in the
rBS-WC vaccine are killed and do not replicate. Second, the
vaccine antigens act locally on the gastro-intestinal mucosa is not
absorbed and does not enter the maternal or foetal circulation.
Third rBS-WC vaccines don’t trigger systemic reactions (e.g. fever)
linked to abortions early in pregnancy. However, no actual safety
studies of the rBS-WC vaccine in pregnancy have been carried out
[12].
The uncertainty regarding the use of the vaccine during
pregnancy has resulted in differing recommendations. The
recommendations from the WHO state the following. ‘‘The
primary targets for cholera vaccination in many endemic areas are
preschool-aged and school-aged children. Other groups that are
especially vulnerable to severe disease and for which the vaccines
are not contraindicated may also be targeted, such as pregnant
women and HIV-infected individuals.’’ [13]. The package insert of
Dukoral, states: ‘‘The effect of DUKORAL [Oral, Inactivated
Travellers’ Diarrhoea and Cholera Vaccine] on embryo-foetal
development has not been assessed and animal studies on
reproductive toxicity have not been conducted. No specific clinical
studies have been performed to address this issue. The vaccine is
therefore not recommended for use in pregnancy. However,
DUKORAL is an inactivated vaccine that does not replicate.
DUKORAL is also given orally and acts locally in the intestine.
Therefore, in theory, DUKORAL should not pose any risk to the
human foetus. Administration of DUKORAL to pregnant women
may be considered after careful evaluation ofthe benefits and
risks.’’ The package insert of the second generation vaccine
(Shanchol ) uses similarly guarded language: ‘‘The vaccine is not
recommended for use in pregnancy. However, Shanchol is a killed
vaccine that does not replicate, is given orally and acts locally in
the intestine. Therefore, in theory, Shanchol should not pose any
risk to the human foetus. Administration of Shanchol to pregnant
women may be considered after careful evaluation of the benefits
and risks in case of a medical emergency or an epidemic.’’
A mass oral cholera vaccination was conducted in Zanzibar in
2009. Pregnant women were advised not to participate in the
campaign. To assess whether any pregnant women had inadver-
tently received the vaccine, and to investigate birth outcomes, we
visited all women residing in the study area and in the
reproductive age group more than nine months after the last dose
of the vaccine had been administered. The objective of the study
was to determine whether there was any difference between the
outcomes of pregnancies exposed and not exposed to the oral rBS-
WC cholera vaccine.
Methods
The study methods have been described in more detail in the
accompanying paper estimating the effectiveness of the vaccine
[14].
Ethics statement
The study was conducted according to the principles expressed
in the Declaration of Helsinki. Individual verbal consent was
obtained from each respondent after the purpose of the study was
explained. The Institutional Review Board of the Government of
Zanzibar (ZAMREC), of the International Vaccine Institute,
Seoul, Korea, and the Research Ethics Review Committee of the
World Health Organization, Geneva, Switzerland approved this
project.
The informed consent process was done in several phases.
Community informed consent was obtained through meetings
with the local leaders (She has). A multistage community outreach
campaign was conducted to disseminate information about the
planned study activities. During the census, individual verbal
informed consent was obtained prior to the interview of each
household head or his or her representative. During the mass
vaccination, individual verbal informed consent was obtained from
each participant or from his or her guardian, if they were less than
18 years of age. In addition, verbal assent from children 12 to 17
years of age was obtained. The participants received information
regarding the vaccine, including advice for children less than 2
years of age and pregnant women not to receive the vaccine.
There was no screening for pregnancy prior to vaccine admin-
istration.
The interview of pregnant women was closely linked with the
census, for which oral consent was provided. Like the census
interview, the interview of pregnant women posed minimal risks
and oral consent was deemed appropriate. Provision of oral
consent by each participant was documented in a logbook. The
use of oral consent was approved by the ethics review boards. After
the surveillance was completed the three ethics review boards were
informed about the conduct and the findings of the birth
surveillance.
Author Summary
Pregnant women are more vulnerable to complications of
cholera than other people. It would be helpful to include
pregnant women in vaccination campaigns against chol-
era but pregnant women and their unborn children are
highly vulnerable to the potential adverse effects of
biological products such as vaccines. The safety of oral
cholera vaccines in pregnant women has up to now not
been evaluated. During a large mass cholera vaccination
campaign in Zanzibar in 2009, women were advised not to
participate if they thought they may be pregnant. The
large majority (955 or 83%) of women residing in the study
area who were to be pregnant during the 9 months
following the vaccinations did not participate in the
campaign. The remaining 196 (17%) women received the
vaccine. A comparison between vaccine exposed and
unexposed pregnancies did not reveal any significant
differences in outcome between the two groups. The small
number of miscarriages, infant deaths and ill infants was
similarly distributed between the two groups. These
findings are reassuring but continued monitoring of this
vaccine when given during pregnancy is recommended.
Safety of the rBS-WC Cholera Vaccine in Pregnancy
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Study site
The archipelago of Zanzibar lies about 50 kilometres east of
mainland Tanzania and consists of two main islands, Unguja and
Pemba, as well as smaller islets. Zanzibar had a population of
about 1.1 million in 2009. In Unguja, we included the shehias of
Chumbuni, Karakana, and Mtopepo, which are informal,
urbanized areas extending from the capital, Zanzibar City also
known as Stonetown. These shehias arose without the corre-
sponding development of adequate water and sanitation facilities.
In Pemba, we included the shehias of Mwambe, Kengeja, and
Shamiani, located in the mainly rural southeast of the island.
Vaccine
Each dose of the rBS-WC cholera vaccine (Dukoral TM, SBL
Vaccine AB, Sweden) consists of ca. 161011 vibrios [12]:
N Vibrio cholerae O1 Inaba classical strain, heat inactivated (ca.
2.561010 vibrios)
N V. cholerae O1 Inaba El Tor strain, formalin inactivated (ca.
2.561010 vibrios)
N V. cholerae O1 Ogawa classical strain, heat inactivated (ca.
2.561010 vibrios)
N V. cholerae O1 Ogawa classical strain, formalin inactivated (ca.
2.561010 vibrios)
N Recombinant cholera toxin B subunit (1 mg)
The full dose of vaccine was mixed with 75 or 150 ml of buffer
solution for participants aged from two to six years and over six
years, respectively.
Census
A formal census was conducted from November to December
2008, collecting demographic and socio-economic information.
Verbal informed consent was obtained from the head of each
household prior to the interviews. The number of household
members, ownership of various capital goods and household
building materials were recorded. Data was directly entered into
handheld computers, also known as personal digital assistants
(PDA) [15]. A unique identification number was assigned to each
resident in the study sites. After the census was completed,
household identification cards were distributed in early January
2009. At the time of card distribution, all healthy, non-pregnant
residents of the study sites who were two years of age and older
were invited to participate in the mass vaccination campaign.
Study residents were requested to bring their household identifi-
cation cards when coming to a vaccination outpost to facilitate
identification. In August 2009, a second census was conducted in
the study sites to update the study population database.
Mass vaccination campaign
The mass vaccination campaign was implemented by the
Expanded Program on Immunization of the Zanzibar Ministry of
Health and Social Welfare with WHO technical support. The
first round of immunizations was conducted from January 11 to
26, 2009, the second round from February 7 to 16, 2009. The
vaccine vial was shaken, opened and its contents poured into a
cup with buffer solution and stirred. The participants drank the
mixture under direct observation and completeness of ingestion
was recorded. During the first round, a card was issued to each
vaccine recipient to record the subject’s name, age, address,
household head, date of vaccination, and completeness of
ingestion of the dose. At the time of dosing, this information
was also recorded in a PDA-based vaccination registry. Only
those who had received a first dose (as documented in the
vaccination card or the PDA registry) were given a second dose of
the vaccine.
Birth surveillance
The birth surveillance was conducted more than 9 months
after the mass vaccination campaign was completed, between
January 15 and February 15, 2010. A list of all women between
15 and 50 years of age at the time of the vaccination campaign
and living in the study area was prepared based on the study
population database. Following training in study procedures
fieldworkers visited the listed women and asked whether they had
been pregnant in 2009. Women who had been pregnant were
asked about the following: the date of delivery, duration and
outcome of the pregnancy based on their last menstrual period,
number of deliveries, age of the last child born before this
delivery, antenatal clinic attendance during this pregnancy and
person who attended the delivery. Birth outcomes were described
as miscarriage or live births. We further defined a miscarriage as
either a spontaneous abortion or a stillbirth. A spontaneous
abortion was defined as a termination of a pregnancy within 20
weeks of conception. A stillbirth was defined as a foetus born after
20 weeks of gestation without a pulse. Live births that died later
during infancy were described as infant deaths. For live births,
the disposition of the baby was recorded. During the visit the field
worker asked whether the baby is free from recurring illness,
without gross malformations, and is feeding, urinating, defecat-
ing, crying, sleeping and growing normally. For the purpose of
this surveillance, a recurrent illness was defined as an illness
lasting more than two weeks or occurring twice or more often
[16]. Only illnesses requiring the attention of medical staff were
included. A gross malformation was defined as a physical defect
present in a baby at birth. It includes any abnormality visible on a
naked baby (e.g. cleft lip or palate, Down syndrome, spina bifida,
limb defects, etc.). Whether feeding, urinating, defecating, crying,
sleeping and growing was within the normal range was recorded
according to the mother’s definition. If the field worker
considered the infant as sick or abnormal, the infant was seen
by a paediatrician. The paediatrician completed a standardized
history, physical examination and assessment and provided
treatment or referral according to national guidelines. The field
workers and paediatricians were blinded regarding the vaccina-
tion status of the mother.
Analysis
The information collected during birth surveillance was linked
to the population census and vaccination databases. Receipt of the
cholera vaccine during the mass immunization program was
ascertained based on the vaccination database. Linkage to the
vaccination registry was made blinded to pregnancy outcome.
Baseline data on socio-behavioural, economic, and environmental
variables were obtained from the census database.
To calculate the date of conception, we subtracted the duration
of the pregnancy (as defined by the mother in weeks based on the
last menstrual period) from the date of delivery. The pregnancy
was considered exposed to the vaccine if the period from
conception to delivery included the dates when the woman
received at least one vaccine dose. Additionally, because it is
difficult to know the exact date of conception, we included
pregnancies with calculated conception dates within two weeks
before ingestion of the first vaccine dose as potentially exposed. A
pregnancy was considered unexposed if the period from two weeks
before the calculated conception date to the date of delivery did
not include receipt of any oral cholera vaccine dose. We compared
Safety of the rBS-WC Cholera Vaccine in Pregnancy
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the frequency of adverse birth outcomes between exposed and
unexposed pregnancies.
The number of miscarriages, live infants and infant deaths (birth
outcomes) among the exposed and unexposed pregnancies were
initially compared using chi-square or Fisher’s exact test, as
appropriate. Characteristics of women who had exposed and
unexposed pregnancies were compared using chi-square and
Student’s t-test for binary/categorical and continuous variables,
respectively. In the assessment of the risk for negative outcomes
(miscarriage and infant sickness, abnormality or death), a stepwise
elimination method was used to select variables most closely
associated with exposure and non-exposure and to fit them into a
logistic regression model. All p values and 95% confidence
intervals were interpreted in a two-tailed fashion. Statistical
significance was designated as a p value less than 0.05. Stata/SE
8 (Stata Corporation, Texas, USA) was used for statistical analysis.
Figure 1. Flow of study participants. *A miscarriage was defined as either an abortion or a stillbirth. An abortion was defined as a termination of
a pregnancy within 20 weeks of conception. A stillbirth was defined as a fetus delivered after 20 weeks of gestation without a pulse.
doi:10.1371/journal.pntd.0001743.g001
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Results
The population census enumerated 14,564 women between 15
and 50 years of age residing in the study sites. During the birth
surveillance, 13,736 (94%) of this population were located and
interviewed. Women who participated had a significantly different
health care utilization pattern, tended to be from a lower socio-
economic background as suggested by the possession of fewer
capital items (mobile phone, bicycle etc.), came from larger
households and tended to be less well educated (Table S1).
Out of the interviewed women, 1,453 (11%) had a delivery in
2009; and 1,151 (79%) of these deliveries occurred during the
period where the foetus could have been exposed to the vaccine.
The large majority 955 (83%) out of these 1,151 mothers had not
been vaccinated; the remaining 196 (17%) mothers had received at
least one dose of the oral cholera vaccine (82 received 1 dose, 114
received 2 doses). The flow of the pregnant women is shown in
Figure 1.
We compared the outcomes of pregnancies exposed and
unexposed to the cholera vaccine (Table 1). There was no
statistically significant difference in the number of miscarriages
among the exposed compared to the unexposed pregnancies [10/
196 (5%) vs. 27/955 (3%), adjusted odds ratio (AOR) 1.62 (95%
confidence interval (95% CI 0.76 to 3.43)]. Similarly, there was no
Table 1. Adjusted odds ratio of exposure to vaccine for negative outcomes using logistic regression models.
Exposed (n =196)
N (%)
Unexposed (n=955)
N (%)
P value un-
adjusted
Adjusted odds
ratio (95% CI)
P value
adjusted
Miscarriages 10 (5.1) 27 (2.8) 0.10 1.621 0.21
Live births 186 (94.9) 928 (97.2) (0.76–3.43)
Deaths 3 (1.6) 13 (1.4) 0.82 1.462 0.56
Live infants 183 (98.4) 915 (98.6) (0.41–5.29)
Sick based on paediatrician’s
examination
8 (4.4) 46 (5.0) 0.70 0.793 0.56
Healthy infants 175 (95.6) 869 (95.0) (0.36–1.75)
1Adjusted for: motorcycle ownership and number of deliveries.
2Adjusted for: household construction materials and sex of the baby.
3Adjusted for: household size and travel.
doi:10.1371/journal.pntd.0001743.t001
Figure 2. Timing of vaccine exposure during pregnancy of the 10 miscarriages.
doi:10.1371/journal.pntd.0001743.g002
Safety of the rBS-WC Cholera Vaccine in Pregnancy
www.plosntds.org 5 July 2012 | Volume 6 | Issue 7 | e1743
statistically significant difference in the number of infant deaths
among the exposed compared to the unexposed non-miscarriage
pregnancies [3/186(2%) vs. 13/928 (1%), AOR 1.46 (95% CI
0.41 to 5.29)]. The frequency of infant illness and abnormalities
among the live infants verified by a paediatrician was 8/183 (4%)
among the exposed versus 46/915 (5%) among the unexposed
(AOR 0.79, 95th CI 0.36 to 1.75). Logistic regression models,
adjusted for variation in background characteristics, found no
significant difference in the frequency of miscarriages, sickness or
abnormality, and infant deaths between the exposed and
unexposed pregnancies.
We assessed the timing of the exposure to the cholera vaccine in
relation to the gestational period of the ten miscarriages (Figure 2).
Vaccine exposure occurred during the first trimester in three,
during the second trimester in four, and during the third trimester
in three pregnancies.
We compared individual and household characteristics of the
mothers who had exposed and unexposed pregnancies (Table 2).
Pregnant women who participated in the mass vaccination
campaign differed in several aspects from pregnant women who
didn’t participate in the vaccinations. The women who received
the vaccine were significantly older, had had more deliveries,
attended antenatal care less frequently, had more frequently lived
in the same household during the past 5 years and lived in a larger
household with lower socio-economic status as suggested by the
ownership of capital items and household construction materials.
Table 2. Comparison of individual and household characteristics between mothers exposed and unexposed to the oral cholera
vaccine.
Exposed Unexposed P value*
n=196 n=955
Mean age (SD) 30.1(7.9) 28.8(7.2) 0.04
Mean no of deliveries (SD) 5.2(2.8) 4.2(2.8) ,.01
No (%) with educational level as follows:
Illiterate 55(28.1) 235(24.7) 0.33
Completed primary level and above 141(71.9) 716(75.3)
No (%) who attended antenatal clinic during this pregnancy 191(97.5) 949(99.4) 0.03
No (%) whose delivery was attended by a health
professional (nurse, clinical officer or doctor)
3(1.5) 13(1.4) 0.85
Mean age of her last child born before this delivery (SD) 3.3(1.9) 3.5(1.8) 0.06
No (%) with twins born during this delivery 6(3.1) 58 (6.1) 0.09
No (%) with household role as follows:
Head of household 10(5.1) 43(4.5) 0.97
Daughter of household head 14(7.1) 63(6.6)
Wife of household head 158(80.6) 776(81.3)
Other 14(7.1) 73(7.6)
No (%) residing during the past 5 years:
In the same household 155(79.1) 668(70.0) 0.01
In another household 41(20.9) 286(30.0)
Mean no of household members (SD) 6.6(2.9) 5.9(2.9) ,.01
No (%) who own or with household members who own a:
Mobile phone 65(33.3) 373(40.6) 0.06
Bicycle 74(37.8) 403(43.7) 0.13
Motorcycle or scooter 11(5.6) 65(7.0) 0.47
Car or truck 1(0.5) 11(1.2) 0.40
No (%) whose household has:
Electricity 52(26.5) 310(33.7) 0.05
A radio 132(67.3) 636(68.9) 0.67
A television set 40(20.4) 223(24.2) 0.26
A refrigerator 15(7.7) 117(12.7) 0.05
A cemented, tiled or carpeted floor (versus mud) 118(60.2) 624(67.5) 0.05
A cemented or tiled wall (versus thatched) 140(71.4) 722(78.1) 0.04
A metal or tiled roof (versus thatched) 172(87.8) 813(88.0) 0.93
A safe main source of drinking water** 130(66.3) 664(71.9) 0.12
*The p-values were derived by comparing the differences between the two groups (t-test for mean comparison for continuous variables and chi-square test for binary/
categorical variables).
**Safe water sources included: protected well, tap water and bottled water; unsafe water sources included: unprotected well, pond, river/stream, spring, and other.
doi:10.1371/journal.pntd.0001743.t002
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Discussion
This is the first report of the safety of the rBS-WC oral cholera
vaccine administered during pregnancy. We found no significant
differences in birth outcomes among pregnancies exposed and
unexposed to the rBS-WC oral cholera vaccine. Among the 196
pregnancies with gestational exposure to the vaccine, there was no
evidence of a statistically significant increase in the number of
foetal losses or infant deaths compared to unexposed pregnancies.
There was a slightly higher percentage of miscarriages in
pregnancies exposed to the oral cholera vaccine than in
pregnancies not exposed. This trend did not reach statistical
significance and is likely explained by chance.
The study has several limitations. First, foetal losses were
probably under-reported since pregnancy is often denied until late
into gestation for complex cultural reasons. Second, and more
importantly, exposure or non-exposure to the vaccine was not
randomized. Instead prior to vaccination women were advised not
to participate in the vaccinations if they were pregnant and there
was no mandatory pregnancy testing prior to vaccination. This
element of self-selection may have led to bias. Third, an element of
recall bias can’t be ruled out, namely women may have recalled
adverse outcomes more frequently when they had been vaccinated
than unvaccinated women. Fourth, the study detected 196
pregnancies. Even though the study is the largest to date, the
overall number of pregnancies (196) is small and has limited power
to detect infrequent adverse events. Fifth our sampling method
does not detect maternal deaths. Finally, 6% of the eligible women
did not participate in this birth surveillance study. Considering
that the large majority (94%) of eligible women participated in the
study it seems unlikely that this finding has introduced bias.
To help ensure the validity of the results, we performed the
following procedures: To ensure the complete detection of all
pregnancies in the study site, we visited and interviewed all women
in reproductive age enumerated in the census. Extensive
information about potentially confounding variables was available
since data on baseline characteristics of individuals and households
were collected during the census and during the interview of the
mothers, which were controlled for in the analyses. Birth outcomes
were linked in a blinded fashion to vaccination status in the
database in order to avoid potential observer bias.
Pregnant women who participated in the mass vaccination
campaign were older, had had more deliveries, came from bigger
households and had lived in the same household for a longer
period than pregnant women who did not participate. Younger
pregnant women from smaller, better-off households may well
perceive themselves at a lower risk for gastro-enteric infections
than more experienced, older women from a lower socio economic
background. Similar observations of an inverse relationship
between participation in free mass vaccination campaigns and
socio-economic status have been reported from Kolkata, India
[17] and Hue, Vietnam [18]. Alternatively younger women from a
higher socio-economic background have a better understanding of
the potential risks of vaccination during pregnancy than women
from a lower socio-economic background.
Conclusions
This study found no significant increase in adverse events
involving the foetus or newborn among pregnant women who
inadvertently received killed oral cholera vaccine. Because the
sample size was small, our findings cannot rule out the possibility
that rBS-WC vaccine could cause adverse events during pregnan-
cy, but the study provides reassurance that such events are not
common. The findings from this study support the current
recommendation that killed oral cholera vaccine is not contrain-
dicated during pregnancy, but the decision to administer the
vaccine should depend on the epidemiological context and after
weighing the potential benefits and risks [12]. Randomized,
controlled studies of the rBS-WC vaccine in pregnant women are
ethically not justifiable, but future, larger mass vaccinations may
allow further evaluation of birth outcomes after inadvertent
exposure of pregnant women to the vaccine.
Supporting Information
Table S1 Baseline characteristics of women who par-
ticipated and didn’t participate in the birth surveillance.
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